Conditionnement : 50mg
Téléphone : +1 850 650 7790
Synonyms: MK-0733, MK 733
| Description | Simvastatin (MK 733) is an HMG-CoA reductase inhibitor (Ki=0.2 nM) with oral activity. Simvastatin has hypolipidemic activity, inhibits hepatic production of cholesterol, and is also used for the prevention of cardiovascular disease. |
| Targets & IC50 | Hepatocyte cells:1.3 nM, MEF cells:36.7 μM, HEK293 cells:11 μM, HMG-CoA reductase:0.1-0.2 nM (Ki), A549 cells:16.3 μM, Hs 68 cells:26.4 μM, L6 cells:229 nM |
| In vitro | METHODS: BCa cells 5637, EJ and T24 were treated with Simvastatin (0.5-40 µM) for 48 h. Cell viability was measured by MTT assay. RESULTS: Simvastatin significantly inhibited the survival of the three BCa cells in a dose-dependent manner. [1] METHODS: Human fibroblast SAEC and four tumor cells MCF7, HepG2, NCH, NCI were treated with Simvastatin (20 µM) for 72 h. Apoptosis was detected by TUNEL. RESULTS: Simvastatin induced apoptosis in different types of human tumor cells, but not in SAEC cells. [2] |
| In vivo | METHODS: To study in vivo activity, Simvastatin (60 mg/kg, aqueous 2% DMSO+30% PEG 400+5% Tween 80) was administered by gavage to C57BL/6J mice once daily for six weeks on a CF diet. RESULTS: Simvastatin treatment reduced serum cholesterol levels by 18%, and retinal cholesterol and lipoprotein cholesterol levels by 24% and 21%, respectively. [3] METHODS: To assay antitumor activity in vivo, Simvastatin (5-50 mg/kg in methylcellulose) was administered to BALB/c nu/nu mice by gavage once daily for three days. Subsequently, colorectal cancer cells COLO205 were subcutaneously inoculated into the right side of the mice. RESULTS: Simvastatin inhibited tumor growth in a xenograft mouse model by inducing tumor cell apoptosis and inhibiting tumor angiogenesis. [4] |
| Synonyms | MK-0733, MK 733 |
| Kinase Assay | For assessment of Akt protein kinase activity in vitro, substrate (2 μg histone H2B or 25 μg eNOS peptide) is incubated with Akt immunoprecipitated from cell lysate using goat polyclonal anti-Akt1 antibody. Kinase reactions are initiated following the addition of reaction components to a final concentration of ATP (50 μM) containing 10 μCi of 32P-γATP, dithiotreitol (1 mM), HEPES buffer (20 mM, pH 7.4), MnCl2 (10 mM), MgCl2 (10 mM). After incubation for 30 min at 30°C, phosphorylated histone H2B is visualized after SDS-PAGE (15%) and autoradiography. To estimate the extent of 32P incorporation into eNOS peptides, each reaction mixture is measured by spotting onto phosphocellulose disc filter and the amount of phosphate incorporated is measured by Cerenkov counting. The wild-type peptide sequence is 1174-RIRTQSFSLQERHLRGAVPWA-1194, and the mutant eNOS peptide is identical except that serine 1179 is substituted by alanine. |
| Molecular Weight | 418.57 |
| Formula | C25H38O5 |
| Cas No. | 79902-63-9 |
| Smiles | O(C(C(CC)(C)C)=O)[C@@H]1[C@]2(C(C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(=O)O3)=C[C@H](C)C1)10 |
| Relative Density. | 1.11 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 100 mg/mL (238.91 mM), Sonication is recommended.  DMSO: 50 mg/mL (119.45 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (11.95 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO/Ethanol
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
